Published in TB and Outbreaks Week, November 17th, 1997
The new agreement grants to Merck exclusive worldwide rights to use Vical's proprietary naked DNA technology for therapeutic vaccines against HIV and HBV. Merck also holds a license to use the technology for a therapeutic vaccine against the human papilloma virus (HPV). Preventive vaccines prime the body's immune system to respond to potential future infections by foreign organisms. Therapeutic vaccines trigger or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.